Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dexcom (DXCM) Operating Leases (2019 - 2025)

Dexcom (DXCM) has disclosed Operating Leases for 7 consecutive years, with $73.4 million as the latest value for Q4 2025.

  • Quarterly Operating Leases rose 12.92% to $73.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $73.4 million through Dec 2025, up 12.92% year-over-year, with the annual reading at $73.4 million for FY2025, 12.92% up from the prior year.
  • Operating Leases for Q4 2025 was $73.4 million at Dexcom, up from $50.6 million in the prior quarter.
  • The five-year high for Operating Leases was $111.3 million in Q1 2021, with the low at $50.6 million in Q3 2025.
  • Average Operating Leases over 5 years is $82.2 million, with a median of $82.8 million recorded in 2022.
  • The sharpest move saw Operating Leases soared 45.32% in 2021, then dropped 28.83% in 2025.
  • Over 5 years, Operating Leases stood at $98.6 million in 2021, then decreased by 4.06% to $94.6 million in 2022, then decreased by 15.33% to $80.1 million in 2023, then decreased by 18.85% to $65.0 million in 2024, then rose by 12.92% to $73.4 million in 2025.
  • According to Business Quant data, Operating Leases over the past three periods came in at $73.4 million, $50.6 million, and $54.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.